References of "Borson-Chazot, F"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHistologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.
Lecomte, Pierre ULiege; Binquet, C.; Le Bras, M. et al

in World Journal of Surgery (2017)

OBJECTIVE: To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death. br-NETs frequency ranges ... [more ▼]

OBJECTIVE: To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death. br-NETs frequency ranges from 3 to 13% and may reach 32% depending on the number of patients evaluated and on the criteria required for diagnosis. METHODS: The 1023-patient series of symptomatic MEN1 patients followed up in a median of 48.7 [35.5-59.6] years by the Groupe d'etude des Tumeurs Endocrines was analyzed using time-to-event techniques. RESULTS: br-NETs were found in 51 patients (4.8%, [95% CI 3.6-6.2%]) and were discovered by imaging in 86% of cases (CT scan, Octreoscan, Chest X-ray, MRI). Median age at diagnosis was 45 years [28-66]. Histological examination showed 27 (53%) typical carcinoids (TC), 16 (31%) atypical carcinoids (AC), 2 (4%) large cell neuroendocrine carcinomas (LCNEC), 3(6%) small cell neuroendocrine carcinomas (SCLC), 3(6%) TC associated with AC. Overall survival was not different from the rest of the cohort (HR 0.29, [95% CI 0.02-5.14]). AC tended to have a worse prognosis than TC (p = 0.08). Seven deaths were directly related to br-NETs (three AC, three SCLC and one LCNEC). Patients who underwent surgery survived longer (p = 10-4) and were metastasis free, while 8 of 14 non-operated patients were metastatic. There were no operative deaths. CONCLUSIONS: Around 5% of MEN1 patients develop br-NETs. br-NETs do not decrease overall survival in MEN1 patients, but poorly differentiated and aggressive br-NETs can cause death. br-NETs must be screened carefully. A biopsy is essential to operate on patients in time. [less ▲]

Detailed reference viewed: 20 (1 ULiège)
Full Text
See detailHypopituitarism in pituitary gigantism (results of an international study)
Rostomyan, L; Daly, Adrian ULiege; Shah, N et al

in Abstract book - Symposium "Perspectives in Endocrinology" Congresses Highlights 2013:ECE Copenhagen, ENDO SF, SFE Paris (2014, February)

Detailed reference viewed: 47 (6 ULiège)
Full Text
See detailHypopituitarism in pituitary gigantism (results of an international study)
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Shah, NS et al

in The 3rd ENEA Workshop : Hypopituitarism - Abstract book (2013, December)

Detailed reference viewed: 29 (4 ULiège)
Full Text
Peer Reviewed
See detailLe gigantisme : Les résultats d'une étude clinique et génétique internationale
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Lila, A et al

in Annales d'Endocrinologie (2013, October), 74

Detailed reference viewed: 43 (8 ULiège)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Tichomirowa, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 57 (6 ULiège)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Tichomirova, M et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 33 (2 ULiège)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULiege; Jaffrain Rea, ML; PETROSSIANS, Patrick ULiege et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 43 (5 ULiège)
Full Text
Peer Reviewed
See detailCyclin dependent kinase inhibitor (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds
Tichomirowa, M.; Lee, M.; Barlier, A. et al

in Endocrine-Related Cancer (2012), 19

Detailed reference viewed: 19 (6 ULiège)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Tichomirowa, M et al

in Abstract book - Aspiring excellence : Pituitary expert forum (2012)

Detailed reference viewed: 22 (2 ULiège)
Full Text
Peer Reviewed
See detailProlactinomas Resistant to Standard Doses of Cabergoline : A multicenter study of 92 patients
VROONEN, Laurent ULiege; Jaffrain-Rea, ML; PETROSSIANS, Patrick ULiege et al

in European Journal of Endocrinology (2012), 167

Detailed reference viewed: 59 (11 ULiège)
Full Text
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULiege; Jaffrain-Rea, M. L.; PETROSSIANS, Patrick ULiege et al

in ENEA Munich - abstract book (2011, December)

Detailed reference viewed: 34 (4 ULiège)
Full Text
Peer Reviewed
See detailGender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d''etude des Tumeurs Endocrines
goudet, p; Bonithon-Kopp, C.; Murat, A. et al

in European Journal of Endocrinology (2011)

Detailed reference viewed: 15 (1 ULiège)
Full Text
Peer Reviewed
See detailCaractéristiques des prolactinomes résistants aux agonistes dopaminergiques
Vroonen, Laurent ULiege; Tamagno, G.; Naves, L. et al

in Annales d'Endocrinologie (2010, September), 71(5), 347

Detailed reference viewed: 46 (6 ULiège)
Full Text
Peer Reviewed
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA): analyse de 86 familles
Beckers, Albert ULiege; Tichomirowa, M.; Pellegata, N. et al

in Annales d'Endocrinologie (2010, September), 71(5), 398

Detailed reference viewed: 25 (9 ULiège)
See detailCyclin dependent kinase inhibitor 1B (CDKN1B) gene mutations in FIPA
Tichomirowa, M. A.; Pellegata, N. S.; Barlier, A. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 20 (3 ULiège)
See detailComprehensive study about the characteristics of 80 dopaminergic agonist resistants prolactinomas
Vroonen, Laurent ULiege; Tamagno, G.; Naves, L. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 22 (5 ULiège)
Full Text
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA) : analyse de 86 familles
Beckers, Albert ULiege; Tichomirowa, M.; Pellegata, N. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 32 (10 ULiège)
Full Text
Peer Reviewed
See detailRisk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.
Goudet, P.; Murat, A.; Binquet, C. et al

in World Journal of Surgery (2010), 34(2), 249-255

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a ... [more ▼]

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a large cohort of MEN1 patients. Methods - Overall, 758 symptomatic MEN1 patients were identified through the GTE network (Groupe d’étude des Tumeurs Endocrines), which involves French and Belgian genetics laboratories responsible for MEN1 diagnosis and 80 clinical reference centers. The causes of death were analyzed. A frailty model, including time-dependent variables, was used to assess the impact of each clinical lesion, except for hyperparathyroidism, on survival. Results - The median follow-up was 6.3 years. Female gender, family history of MEN1, and recent diagnosis were associated with a lower risk of death. Compared with nonaffected patients, those with thymic tumors (hazard ratio [HR] = 4.64, 95% CI = 1.73-12.41), glucagonomas–vipomas–somatostatinomas (HR = 4.29, 95% CI = 1.54-11.93), nonfunctioning pancreatic tumors (HR = 3.43, 95% CI = 1.71-6.88), and gastrinoma (HR = 1.89, 95% CI = 1.09-3.25) had a higher risk of death after adjustment for age, gender, and diagnosis period. The increased risk of death among patients with adrenal tumors was not significant, but three patients died from aggressive adrenal tumors. Pituitary tumors, insulinomas, and bronchial tumors did not increase the risk of death. The proportion of MEN1-related deaths decreased from 76.8 to 71.4% after 1990. Conclusions - The prognosis of MEN1 disease has improved since 1980. Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death. Rare but aggressive adrenal tumors may also cause death. Most deaths were related to MEN1. New recommendations on abdominal and thoracic imaging are required. [less ▲]

Detailed reference viewed: 36 (2 ULiège)
Full Text
Peer Reviewed
See detailClinical characteristics and therapeutic responses in patients with Germ-line AIP mutations and pituitary adenomas : An international collaborative study
Daly, Adrian ULiege; Tichomirowa, Maria A.; Petrossians, Patrick ULiege et al

in Journal of Clinical Endocrinology and Metabolism (2010), 95(11),

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features ... [more ▼]

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. <br />Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. <br />Design: This study was an international, multicenter, retrospective case collection/database analysis. <br />Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. <br />Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. <br />Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. <br />Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. [less ▲]

Detailed reference viewed: 138 (50 ULiège)
See detailAn analysis of the role of cyclin dependant kinase inhibitor 1B (CDKN1B) gene mutations in 86 families with familial isolated pituitary adenomas (FIPA)
Tichomirova, M. A.; Daly, Adrian ULiege; Pujol, Julien ULiege et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 32 (8 ULiège)